Back
Galectin Therapeutics 10K Form
Sell
40
GALT
Galectin Therapeutics
Last Price:
2.75
Seasonality Move:
14%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-15 | 10Q | GALT/Galectin Therapeutics Quarterly |
| 2023-11-13 | 10Q | GALT/Galectin Therapeutics Quarterly |
| 2023-08-14 | 10Q | GALT/Galectin Therapeutics Quarterly |
| 2023-05-15 | 10Q | GALT/Galectin Therapeutics Quarterly |
| 2022-11-14 | 10Q | GALT/Galectin Therapeutics Quarterly |
| 2022-08-15 | 10Q | GALT/Galectin Therapeutics Quarterly |
Receive GALT News And Ratings
See the #1 stock for the next 7 days that we like better than GALT
GALT Financial Statistics
Sales & Book Value
| Annual Sales: | -- |
|---|---|
| Cash Flow: | $-8.54M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-1.52 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.73000 |
|---|---|
| Net Income (TTM): | $-45.08M |
| Gross Margin: | $0 |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Galectin Therapeutics Earnings Forecast
Key Galectin Therapeutics Financial Ratios
- The Interest Expense is -6.80% of Operating Income.
- Per Share Earnings over the last 23 years have been positive in 11 years.
Galectin Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | GALT |
| CUSIP: | 363225 |
| Website: | galectintherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
GALT Technical Analysis vs Fundamental Analysis
Sell
40
Galectin Therapeutics (GALT)
is a Sell
Is Galectin Therapeutics a Buy or a Sell?
-
Galectin Therapeutics stock is rated a Sell
The current Galectin Therapeutics [GALT] share price is $2.69. The Score for GALT is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.